ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1832

Increased Interferon b Expression in Bone Marrow Mediates a Senescent Phenotype and Impaired Production of Immunomodulatory Factors By SLE Mesenchymal Stromal Cells

Lin Gao1, Jennifer H. Anolik2 and R. John Looney2, 1medicine- allergy, immunology and rheumatology, University of Rochester Medical Center, Rochester, NY, 2Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Bone marrow, interferons, Mesenchymal stem cells and systemic lupus erythematosus (SLE), Senescent Cells

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Bone marrow mesenchymal stromal cells (MSCs) are multipotent stem cells that create a special microenvironment for hematopoiesis and immunity. MSCs display robust immunomodulatory properties and transplantation of human MSC significantly improves nephritis in murine models of lupus. Immunomodulation by MSCs from lupus patients appears to be impaired, but the mechanisms underlying this defect is unknown. Our previous studies identified an IFN-I signature in SLE bone marrow (BM) and peripheral blood. In fibroblasts, prolonged treatment with IFNb, but not IFNα, has been shown to induce senescence through activation of reactive oxygen species (ROS), ATM and p53 DNA damage and repair (DDR) pathways. Here we investigate whether human SLE MSCs undergo senescence, the potential role of IFNb as a mediator in the SLE BM, and the implications for SLE pathogenesis.

Methods: SLE patients fulfilling ACR classification criteria and healthy controls were recruited under an IRB approved protocol (n=6 each). BM MSCs were isolated with low density Ficoll/Hypaque (1.073 g/ml) and grown in tissue culture. MSC phenotype was verified by flow cytometry. MSCs were studied using immunocytochemistry, real-time PCR, western blotting, comet assay for DNA damage, beta-galactosidase assay and RNA interference.

Results: The expression of IFNb was increased 5 folds (p<0.05) and IFNβ specific genes were significantly elevated in SLE MSCs. In addition, SLE MSCs displayed significantly reduced proliferation rate, increased production of ROS, increased DDR, and senescence associate secretory phenotype (SASP) as evidenced by increased cytokine production (all p<0.05): IL6 (4x), IL8 (8x), GRO1(9x), MCP2 (7x), RANTE1 (5x), GM-CSF (7x). The expression of immunomodulatory factors was significantly reduced (all p < 0.05): TGFβ (4x), IDO1 (3x) and LIF (10x). To begin to explore the signalling pathways that may mediate IFNB activation and DNA damage, we examined the level of Mitochondrial Antiviral Signaling Protein (MAVS), an intracytoplasmic nucleic acid sensor (also known as Interferon Beta Promoter Stimulator Protein 1). MAVS was positively correlated with the level of IFNb (r > 0.9, p< 0.01), and strikingly, silencing MAVs inhibited IFNb expression and reversed the SASP in SLE MSCs.

Conclusion: The relative contribution of IFNα vs. IFNb to SLE disease pathogenesis remains unclear. IFNb has distinct features as compared to IFNα with higher affinity binding to IFN-I receptors, distinct gene transcripts and induction of senescence in fibroblasts. Our current data suggest that SLE BM MSCs produce IFNb, have increased ROS, DDR and SASP, decreased production of immunomodulatory factors, and elevated levels of MAVS. As a key regulator of IFNb expression, the expression of MAVS is highly correlated with the expression of IFNb. In addition, silencing MAVS disrupts IFNb production and rescues SASP in SLE MSCs. Our novel findings of an IFNb positive feedback loop and related SASP in SLE BM MSCs highlight a novel role for IFNb activation in SLE pathogenesis. Moreover, the essential role of MAVS in the IFNb positive feedback loop suggests dysregulated intracytoplasmic nucleic acid sensing and potential novel therapeutic targets for SLE treatment.


Disclosure: L. Gao, None; J. H. Anolik, None; R. J. Looney, None.

To cite this abstract in AMA style:

Gao L, Anolik JH, Looney RJ. Increased Interferon b Expression in Bone Marrow Mediates a Senescent Phenotype and Impaired Production of Immunomodulatory Factors By SLE Mesenchymal Stromal Cells [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/increased-interferon-b-expression-in-bone-marrow-mediates-a-senescent-phenotype-and-impaired-production-of-immunomodulatory-factors-by-sle-mesenchymal-stromal-cells/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-interferon-b-expression-in-bone-marrow-mediates-a-senescent-phenotype-and-impaired-production-of-immunomodulatory-factors-by-sle-mesenchymal-stromal-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology